Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 28, Issue 4, 2010, Pages 525-531

  Touma, Zahi ^a   Gladman, Dafna D ^a   Tulloch Reid, Desiree ^a   Toloza, Sergio M ^a   Ibañez, Dominique ^a   Fortin, Paul R ^a   Urowitz, Murray B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autoantibodies; Outcomes; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD; DISEASE COURSE; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 79952046799     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Reichlin M. Diagnosis criteria and serology. In: Clinical Management of Systemic Lupus Erythematosus. New York Grune and Stratton 1983.
2. ISENBERG DA, MANSON JJ, EHRENSTEIN MR, RAHMAN A. Fifty years of anti-ds DNA antibodies are we approaching journey's end? Rheumatology (Oxford). 2007; 46: 1052-6.
3. BARADA FA JR, ANDREWS BS, DAVIS JST, TAYLOR RP. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum 1981; 24: 1236-44.
4. SAWALHA AH, HARLEY JB. Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16: 534-40.
5. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
6. Prasad R, Ibanez D, Gladman D, Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 2006; 15: 285-91.
7. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008; 30: 74-83.
8. SHERER Y, GORSTEIN A, FRITZLER MJ, SHOENFELD Y. Autoantibody explosion in systemic lupus erythematosus more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004; 34: 501-37.
9. CERIBELLI A, CAVAZZANA I, FRANCESCHINI F, QUINZANINI M, RIZZINI FL, CATTANEO R. Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2008; 26: 117-20.
10. PALOMO I, SEGOVIA F, ORTEGA C, PIERANGELI S. Antiphospholipid syndrome a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol 2009; 27: 668-77.
11. SANCHEZ-GUERRERO J, LEW RA, FOSSEL AH, SCHUR PH. Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1055-61.
12. BENITO-GARCIA E, SCHUR PH, LAHITA R. Guidelines for immunologic laboratory testing in the rheumatic diseases anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004; 51: 1030-44.
13. GUSSIN HA, IGNAT GP, VARGA J, TEODORESCU M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 376-83.
14. NEOGI T, GLADMAN DD, IBANEZ D, UROWITZ M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006; 33: 1785-8.
15. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
16. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al. Cross-cultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992; 19: 608-11.
17. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices international validation. J Rheumatol 1994; 21: 1468-71.
18. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI a disease activity index for systemic lupus erythematosus. J Rheumatol 1993; 20: 657-60.
19. IBANEZ D, UROWITZ MB, GLADMAN DD. Summarizing disease features over time I Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 1977-82.
20. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-6.
21. GLADMAN DD, UROWITZ MB, GOLDSMITH CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-13.
22. ARBUCKLE MR, JAMES JA, KOHLHASE KF, RUBERTONE MV, DENNIS GJ, HARLEY JB. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001; 54: 211-9.